Circular Genomics secured exclusive commercial rights to intellectual property from Washington University in St. Louis and the Max Delbrück Center covering circular RNA (circRNA) biomarkers for Alzheimer’s disease. The licenses grant access to foundational IP on identifying and measuring circRNA signatures across the Alzheimer’s continuum, from preclinical stages through symptomatic disease. Circular Genomics said the deals strengthen its circRNA platform and position the company for partnerships and commercialization in neurodegenerative diagnostics. The move underscores growing industry interest in noncoding RNA biomarkers and competitive positioning around early detection tools for Alzheimer’s.